Robert Chess has sold stock and made no open-market buys since Jun 2016

Robert (Rob) Chess is a life sciences entrepreneur and corporate director who serves as Lead Director on the board of Twist Bioscience Corp. (NASDAQ: TWST), a synthetic biology company focused on high‑throughput DNA synthesis.( He has been a director at Twist Bioscience since 2014 and currently chairs the Nominating and Corporate Governance Committee and serves on the Compensation Committee, while also engaging in regular insider trading activity in the company’s stock as disclosed in SEC-related reporting.( In addition to his Twist role, Chess is Chairman of Nektar Therapeutics, Chairman of BigHat Biosciences, Chairman of Issio Solutions, and has served on the boards of multiple biotechnology and technology companies, reflecting a long career leading and advising emerging and established firms in health care, synthetic biology, and industrial biotechnology.(

Chess’s earlier career includes serving as CEO and later long‑term chairman of Nektar Therapeutics, co‑founding and leading Penederm (a dermatology company that went public and was acquired by Mylan Laboratories), acting as start‑up CEO and later chairman of OPX Biotechnologies (sold to Cargill), and co‑founding Biota Technologies, an early pioneer in using DNA sequencing for energy and industrial applications.( He also worked in public policy as Associate Director of Economic and Domestic Policy in the George H. W. Bush administration, and is a long‑time Lecturer at Stanford Graduate School of Business, where he teaches on entrepreneurship and life sciences.( Chess holds a BS in engineering with honors from Caltech and an MBA from Harvard Business School, and credits his early experience at Intel under Andy Grove and Gordon Moore as formative to his management approach.(

Written by Perplexity from public sources.